AMLProfiler going into clinical trails in 2012

The AMLProfiler -an advanced microrarray-based prognostic for Acute Myeloid Leukaemia (AML) – has been developed in collaboration between Skyline Diagnostics and Crosslinks funded by the Netherlands Center for Translational Molecular Medicine (CTMM). It has now completed development and is entering clinical trials in the second half of 2012 with an expected final FDA submission by the end of 2012, and showcases a new architecture for future diagnostic tests – more information.